Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Genitourinary Cancer · Published 2026-07-13 · DOI 10.1016/j.clgc.2026.102625

Free full text

Authors (8)

Ahmad Basharat, Muhammad Shaheer Mannan, Muhammad Raffey Shabbir, Muhammad Waqas Khan, Tuba Basit, Robin Park, Juskaran Chadha, Moazzam Shahzad

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Basharat, A., Mannan, M., Shabbir, M., et al. (2026). Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2026.102625

Related articles